Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial
Joanna Sadowska/LinkedIn
Dec 2, 2025, 09:50

Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial

Joanna Sadowska, Biopharma Account Specialist, shared on LinkedIn:

”Big News – Bayer’s asundexian reduces ischaemic stroke risk in Phase 3 clinical trial

Bayer has announced positive Phase 3 results from the OCEANIC-STROKE study evaluating asundexian, an investigational once-daily oral Factor XIa inhibitor, for secondary stroke prevention.

This is the first study that successfully completed Phase 3 for Factor XIa.

Approximately 12 million people worldwide experience a stroke each year, with 20-30% being recurrent strokes.

One in five stroke survivors will have another stroke within five years, and these recurrent strokes tend to be more disabling and carry a higher mortality risk than first strokes.

Asundexian is a direct Factor XIa inhibitor designed to reduce thrombus formation that can lead to vessel blockage.

It has a novel mechanism targeting the coagulation pathway differently from current antiplatelet therapies.

Asundexian has received FDA Fast Track Designation for stroke prevention in this patient population.”

Joanna Sadowska

Stay informed with Hemostasis Today.

asundexian Bayer Biopharma Factor XIa Inhibitor FDA Health Hematology Hemostasis Today ischaemic stroke Medicine OCEANIC-STROKE Recurrent Strokes stroke prevention
NewsFeed